Evidence map›Paper›PMID 33805776›Full record

ArticleCancers2021

Establishing the Clinical Utility of ctDNA Analysis for Diagnosis, Prognosis, and Treatment Monitoring of Retinoblastoma: The Aqueous Humor Liquid Biopsy.

Liya Xu, Mary E Kim, Ashley Polski, Rishvanth K Prabakar, Lishuang Shen, Chen-Ching Peng, Mark W Reid, Patricia Chévez-Barrios, Jonathan W Kim, Rachana Shah and 7 more

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04959097 (Retinoblastoma Patient Clinical Database and Tissue Repository), which is not on this map. Cited by 42 papers.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed
8.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04959097 recruitingnot on this map

Retinoblastoma Patient Clinical Database and Tissue Repository

Typeobservational_patient_registrySponsorChildren's Hospital Los AngelesRan2017 to 2030Enrolled800ConditionsRetinoblastoma, Retinoblastoma Bilateral, Retinoblastoma Unilateral
3 · Its place in the literature

Who cites it

42 citing papers in PubMed, 65 citations in OpenAlex.

  1. Digital PCR Quantification of a CirculatingInternational journal of molecular sciences · 2026
    Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Observational
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 3 institutions in 1 country.

Liya XuThe Vision Center at Children's Hospital Los Angeles, Los Angeles, CA 90027, USA.ORCID 0000-0002-5501-2039
Mary E KimThe Vision Center at Children's Hospital Los Angeles, Los Angeles, CA 90027, USA.ORCID 0000-0002-7986-6119
Ashley PolskiThe Vision Center at Children's Hospital Los Angeles, Los Angeles, CA 90027, USA.ORCID 0000-0001-6301-6892
Rishvanth K PrabakarDepartment of Molecular and Computational Biology, University of Southern California, Los Angeles, CA 90007, USA.
Lishuang ShenCenter for Personalized Medicine, Department of Pathology and Laboratory Medicine, Children's Hospital Los Angeles, Los Angeles, CA 90027, USA.ORCID 0000-0002-0436-0199
Chen-Ching PengThe Vision Center at Children's Hospital Los Angeles, Los Angeles, CA 90027, USA.
Mark W ReidThe Vision Center at Children's Hospital Los Angeles, Los Angeles, CA 90027, USA.ORCID 0000-0002-1942-225X
Patricia Chévez-BarriosOphthalmic Pathology, Department of Pathology and Genomic Medicine, Houston Methodist Hospital, Houston, TX 77030, USA.
Jonathan W KimThe Vision Center at Children's Hospital Los Angeles, Los Angeles, CA 90027, USA.
Rachana ShahCancer and Blood Disease Institute at Children's Hospital Los Angeles, Los Angeles, CA 90027, USA.
Rima JubranCancer and Blood Disease Institute at Children's Hospital Los Angeles, Los Angeles, CA 90027, USA.
Peter KuhnDepartment of Biological Sciences, Dornsife College of Letters, Arts, and Sciences, University of Southern California, Los Angeles, CA 90007, USA.
David CobrinikThe Vision Center at Children's Hospital Los Angeles, Los Angeles, CA 90027, USA.
Jaclyn A BiegelCenter for Personalized Medicine, Department of Pathology and Laboratory Medicine, Children's Hospital Los Angeles, Los Angeles, CA 90027, USA.
Xiaowu GaiCenter for Personalized Medicine, Department of Pathology and Laboratory Medicine, Children's Hospital Los Angeles, Los Angeles, CA 90027, USA.
James HicksDepartment of Biological Sciences, Dornsife College of Letters, Arts, and Sciences, University of Southern California, Los Angeles, CA 90007, USA.
Jesse L BerryThe Vision Center at Children's Hospital Los Angeles, Los Angeles, CA 90027, USA.ORCID 0000-0002-8907-9100
University of Southern California · USChildren's Hospital of Los Angeles · USMethodist Hospital · US

Funding

USC/NORRIS COMPREHENSIVE CANCER CENTER (CORE) SUPPORTP30CA014089 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI William Dean Wallace · 1985 to 2026
$181.4M
Ophthalmic Therapeutics Engineering CoreP30EY029220 · NEI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI Mahnaz Shahidi · 2018 to 2026
$6.5M
Development of a surrogate liquid biopsy from the aqueous humor in retinoblastoma eyes.K08CA232344 · NCI · CHILDREN'S HOSPITAL OF LOS ANGELES · PI BERRY, JESSE L · 2018 to 2022
$1.1M
American Cancer Society IRG-16-181-57Carol Vassiliadis Research Fund N/AHyundai Hope On Wheels RGA012351Institute for Families, Inc., Children's Hospital Los Angeles N/AKnights Templar Eye Foundation N/ALarry and Celia Moh Foundation N/ANational Cancer Institute of the National Institute of Health Award K08CA232344Nautica Foundation N/ANCI NIH HHS P30CA014089NIH HHS P30EY029220Research to Prevent Blindness, an unrestricted departmental grant N/AUSC Dornsife College of Letters, Arts and Sciences N/AVicky Joseph Research Fund N/AWright Foundation N/A
6 · The paper itself

Abstract

Because direct tumor biopsy is prohibited for retinoblastoma (RB), eye-specific molecular biomarkers are not used in clinical practice for RB. Recently, we demonstrated that the aqueous humor (AH) is a rich liquid biopsy source of cell-free tumor DNA. Herein, we detail clinically-relevant molecular biomarkers from the first year of prospective validation data. Seven eyes from 6 RB patients who had AH sampled at diagnosis and throughout therapy with ≥12 months of follow-up were included. Cell-free DNA (cfDNA) from each sample was isolated and sequenced to assess genome-wide somatic copy number alterations (SCNAs), followed by targeted resequencing for pathogenic variants using a

Indexed as

aqueous humorctDNAliquid biopsyprecision oncologyretinoblastomaSCNA

Identifiers

PMID33805776
PMCPMC8001323
OpenAlexW3137097395

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.